These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 32808071)

  • 1. Model-based simulation to support the extended dosing regimens of atezolizumab.
    Chou CH; Hsu LF
    Eur J Clin Pharmacol; 2021 Jan; 77(1):87-93. PubMed ID: 32808071
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alternative dosing regimens for atezolizumab: an example of model-informed drug development in the postmarketing setting.
    Morrissey KM; Marchand M; Patel H; Zhang R; Wu B; Phyllis Chan H; Mecke A; Girish S; Jin JY; Winter HR; Bruno R
    Cancer Chemother Pharmacol; 2019 Dec; 84(6):1257-1267. PubMed ID: 31542806
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In Silico Re-Optimization of Atezolizumab Dosing Using Population Pharmacokinetic Simulation and Exposure-Response Simulation.
    Peer CJ; Schmidt KT; Arisa O; Richardson WJ; Paydary K; Goldstein DA; Gulley JL; Figg WD; Ratain MJ
    J Clin Pharmacol; 2023 Jun; 63(6):672-680. PubMed ID: 36624662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation.
    Lala M; Li TR; de Alwis DP; Sinha V; Mayawala K; Yamamoto N; Siu LL; Chartash E; Aboshady H; Jain L
    Eur J Cancer; 2020 May; 131():68-75. PubMed ID: 32305010
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Results of a Dose-Finding Phase 1b Study of Subcutaneous Atezolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer.
    Felip E; Burotto M; Zvirbule Z; Herraez-Baranda LA; Chanu P; Kshirsagar S; Maiya V; Chan P; Pozzi E; Marchand M; Monchalin M; Tanaka K; Tosti N; Wang B; Restuccia E
    Clin Pharmacol Drug Dev; 2021 Oct; 10(10):1142-1155. PubMed ID: 33788415
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population Pharmacokinetics and Exposure-Response Relationship of Zimberelimab in Chinese Patients with Advanced Tumors.
    Yang F; Lu Y; Bai L; Deng C; Liu Z; Sun Z; Li L; Wang S; Zhou L; Feng H; Yan S; Zhu J
    Clin Pharmacol Drug Dev; 2024 Aug; 13(8):897-906. PubMed ID: 39010677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population pharmacokinetic analysis of patritumab, a HER3 inhibitor, in subjects with advanced non-small cell lung cancer (NSCLC) or solid tumors.
    Yoshiba S; Jansen M; Matsushima N; Chen S; Mendell J
    Cancer Chemother Pharmacol; 2016 May; 77(5):987-96. PubMed ID: 27017616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of dosing strategy for pembrolizumab for oncology indications.
    Freshwater T; Kondic A; Ahamadi M; Li CH; de Greef R; de Alwis D; Stone JA
    J Immunother Cancer; 2017; 5():43. PubMed ID: 28515943
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extension of the Alternative Intravenous Dosing Regimens of Atezolizumab into Combination Settings through Modeling and Simulation.
    Liu SN; Marchand M; Liu X; Ingle G; Maiya V; Graupner V; Elze MC; Chan P; Hsu JC; Lin A; Vadhavkar S; Wu B; Bruno R
    J Clin Pharmacol; 2022 Nov; 62(11):1393-1402. PubMed ID: 35576521
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population pharmacokinetics, exposure-safety, and immunogenicity of atezolizumab in pediatric and young adult patients with cancer.
    Shemesh CS; Chanu P; Jamsen K; Wada R; Rossato G; Donaldson F; Garg A; Winter H; Ruppel J; Wang X; Bruno R; Jin J; Girish S
    J Immunother Cancer; 2019 Nov; 7(1):314. PubMed ID: 31753029
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population Pharmacokinetics of Erlotinib in Patients With Non-small Cell Lung Cancer: Its Application for Individualized Dosing Regimens in Older Patients.
    Evelina Cardoso ; Guidi M; Khoudour N; Pascaline Boudou-Rouquette ; Fabre E; Tlemsani C; Arrondeau J; François Goldwasser ; Vidal M; Schneider MP; Wagner AD; Widmer N; Blanchet B; Csajka C
    Clin Ther; 2020 Jul; 42(7):1302-1316. PubMed ID: 32631634
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of intravenous and subcutaneous exposure supporting dose selection of subcutaneous belimumab systemic lupus erythematosus Phase 3 program.
    Yapa SW; Roth D; Gordon D; Struemper H
    Lupus; 2016 Nov; 25(13):1448-1455. PubMed ID: 27072354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alternate Pembrolizumab Dosing Interval in Advanced NSCLC with PD-L1 TPS ≥ 50%: 3 Weekly Compared to 6 Weekly Dosing.
    Jones L; Rittberg R; Leung B; Shokoohi A; Pender A; Wong S; Al-Hashami Z; Wang Y; Ho C
    Curr Oncol; 2022 Nov; 29(11):8686-8692. PubMed ID: 36421338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Model-informed drug development approach supporting approval of the 4-week (Q4W) dosing schedule for nivolumab (Opdivo) across multiple indications: a regulatory perspective.
    Bi Y; Liu J; Furmanski B; Zhao H; Yu J; Osgood C; Ward A; Keegan P; Booth BP; Rahman A; Wang Y
    Ann Oncol; 2019 Apr; 30(4):644-651. PubMed ID: 30715147
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer.
    Long GV; Tykodi SS; Schneider JG; Garbe C; Gravis G; Rashford M; Agrawal S; Grigoryeva E; Bello A; Roy A; Rollin L; Zhao X
    Ann Oncol; 2018 Nov; 29(11):2208-2213. PubMed ID: 30215677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changing Body Weight-Based Dosing to a Flat Dose for Avelumab in Metastatic Merkel Cell and Advanced Urothelial Carcinoma.
    Novakovic AM; Wilkins JJ; Dai H; Wade JR; Neuteboom B; Brar S; Bello CL; Girard P; Khandelwal A
    Clin Pharmacol Ther; 2020 Mar; 107(3):588-596. PubMed ID: 31553054
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics (PK) of Tiragolumab in First-in-Human Study in Patients with Mixed Solid Tumors (GO30103).
    Garralda E; Oh DY; Italiano A; Bedard PL; Delord JP; Calvo E; LoRusso P; Wainberg Z; Cervantes A; Rodriguez-Vida A; Shemesh CS; Sane R; Mendus D; Ding H; Hendricks R; Meng R; Cho BC; Kim TW; Wu B
    J Clin Pharmacol; 2024 May; 64(5):544-554. PubMed ID: 38105505
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pembrolizumab Every 6 Weeks Versus Every 3 Weeks in Advanced Non-Small Cell Lung Cancer.
    Dubé-Pelletier M; Labbé C; Côté J; Pelletier-St-Pierre AA
    Oncologist; 2023 Nov; 28(11):969-977. PubMed ID: 37364568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.
    Rosenberg JE; Hoffman-Censits J; Powles T; van der Heijden MS; Balar AV; Necchi A; Dawson N; O'Donnell PH; Balmanoukian A; Loriot Y; Srinivas S; Retz MM; Grivas P; Joseph RW; Galsky MD; Fleming MT; Petrylak DP; Perez-Gracia JL; Burris HA; Castellano D; Canil C; Bellmunt J; Bajorin D; Nickles D; Bourgon R; Frampton GM; Cui N; Mariathasan S; Abidoye O; Fine GD; Dreicer R
    Lancet; 2016 May; 387(10031):1909-20. PubMed ID: 26952546
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Pharmacokinetics and Pharmacodynamics of Atezolizumab in Metastatic Urothelial Carcinoma.
    Stroh M; Winter H; Marchand M; Claret L; Eppler S; Ruppel J; Abidoye O; Teng SL; Lin WT; Dayog S; Bruno R; Jin J; Girish S
    Clin Pharmacol Ther; 2017 Aug; 102(2):305-312. PubMed ID: 27981577
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.